Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

832 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting.
Kato R, Ikarashi D, Matsuura T, Maekawa S, Kato Y, Kanehira M, Takata R, Tokuyama R, Tamai K, Harigai N, Nakazaki Y, Obara W. Kato R, et al. Among authors: maekawa s. Transl Oncol. 2020 Jun;13(6):100771. doi: 10.1016/j.tranon.2020.100771. Epub 2020 May 3. Transl Oncol. 2020. PMID: 32375081 Free PMC article.
Dysuria therapeutic agents as an independent prognostic factor for the primary recurrence of non-muscle invasive bladder cancer: a propensity score matching study.
Kato Y, Ikarashi D, Kikuchi D, Takayama M, Kanzaki S, Ito A, Tamura D, Matsuura T, Maekawa S, Kato R, Kanehira M, Takata R, Sugimura J, Obara W. Kato Y, et al. Among authors: maekawa s. J Int Med Res. 2021 Aug;49(8):3000605211037478. doi: 10.1177/03000605211037478. J Int Med Res. 2021. PMID: 34407681 Free PMC article.
Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting.
Ikarashi D, Kitano S, Tsuyukubo T, Takenouchi K, Nakayama T, Onagi H, Sakaguchi A, Yamashita M, Mizugaki H, Maekawa S, Kato R, Kato Y, Sugai T, Nakatsura T, Obara W. Ikarashi D, et al. Among authors: maekawa s. Br J Cancer. 2022 Mar;126(4):606-614. doi: 10.1038/s41416-021-01628-y. Epub 2021 Nov 15. Br J Cancer. 2022. PMID: 34782748 Free PMC article.
832 results